The Immune Response Corporation Presents Data at the International Congress of Immunology on HIV Product Candidate IR103
27 Julio 2004 - 10:00AM
PR Newswire (US)
The Immune Response Corporation Presents Data at the International
Congress of Immunology on HIV Product Candidate IR103 - REMUNE(R)
and IR103 Development on Track - CARLSBAD, Calif., July 27
/PRNewswire-FirstCall/ -- The Immune Response Corporation
(NASDAQ:IMNR), a biopharmaceutical company dedicated to becoming a
leading immune-based therapy company in HIV and multiple sclerosis
(MS), presented research results at the International Congress of
Immunology in Montreal demonstrating that IR103 generated robust
HIV-1 specific immune responses. IR103 combines the Company's
patented HIV-1 Immunogen with the immunostimulatory oligonucleotide
adjuvant Amplivax(TM). "We are pleased with the promising results
and clinical progress of both HIV product candidates, REMUNE(R) and
IR103," said John N. Bonfiglio, Ph.D., Chief Executive Officer of
The Immune Response Corporation. "The REMUNE(R) Phase II trials in
Italy and Spain and the IR103 clinical trial in Canada and the UK
are all on track and we are looking forward to seeing the data."
Investigators presented a preclinical study in which mice immunized
subcutaneously with IR103 showed significantly enhanced production
of a number of key markers of HIV-1 specific immune responses.
Importantly, the study demonstrated that IR103 increases HIV-1
specific immune responses when administered with and without
Incomplete Freund's Adjuvant (IFA). Amplivax(TM) was developed by
Hybridon, Inc. (AMEX:HBY) and has been licensed to The Immune
Response Corporation. About The Immune Response Corporation The
Immune Response Corporation (NASDAQ:IMNR) is a biopharmaceutical
company dedicated to becoming a leading immune-based therapy
company in HIV and multiple sclerosis (MS). The Company's HIV
products are based on its patented whole-killed virus technology,
co-invented by Company founder Dr. Jonas Salk, to stimulate HIV
immune responses. REMUNE(R), currently in Phase II clinical trials,
is being developed as a first-line treatment for people with
early-stage HIV. The Company has initiated development of a new
immune-based therapy, IR103, which incorporates a second-generation
immunostimulatory oligonucleotide adjuvant. The Immune Response
Corporation is also developing an immune-based therapy for MS,
NeuroVax(TM), which is currently in Phase II and has shown
potential therapeutic value for this difficult-to-treat disease.
Please visit The Immune Response Corporation on the World Wide Web
at http://www.imnr.com/ This news release contains forward-looking
statements. Forward-looking statements are often signaled by forms
of words such as should, could, will, might, plan, projection,
forecast, expect, guidance, potential and developing. Actual
results could vary materially from those expected due to a variety
of risk factors, including whether the Company will continue as a
going concern and successfully raise proceeds from financing
activities sufficient to fund operations and additional clinical
trials of REMUNE(R), NeuroVax(TM) or IR103, the uncertainty of
successful completion of any such clinical trials, the fact that
the Company has not succeeded in commercializing any drug, the risk
that REMUNE(R), NeuroVax(TM) or IR103 might not prove to be
effective as either a therapeutic or preventive vaccine, whether
future trials will be conducted and whether the results of such
trials will coincide with the results of REMUNE(R), NeuroVax(TM) or
IR103 in preclinical trials and/or earlier clinical trials. These
risks, among others, are set forth in The Immune Response
Corporation's SEC filings including, but not limited to, its Annual
Report on Form 10-K for the year ended December 31, 2003, and any
subsequent Quarterly Reports on Form 10-Q. The Company undertakes
no obligation to update the results of these forward-looking
statements to reflect events or circumstances after today or to
reflect the occurrence of unanticipated events. REMUNE(R) is a
registered trademark of The Immune Response Corporation.
NeuroVax(TM) is a trademark of The Immune Response Corporation. For
further information, please contact: Media, Laura Silver of Sam
Brown Inc., +1-310-551-9940, , or Investor Relations, Kathy Waller
of Financial Relations Board, +1-312-266-7800, , both for The
Immune Response Corporation; or Michael K. Green, Chief Financial
Officer of The Immune Response Corporation, +1-760-431-7080, .
DATASOURCE: The Immune Response Corporation CONTACT: Media, Laura
Silver of Sam Brown Inc., +1-310-551-9940, ; or Investor Relations,
Kathy Waller of Financial Relations Board, +1-312-266-7800, ; or
Michael K. Green, Chief Financial Officer of The Immune Response
Corporation, +1-760-431-7080, Web site: http://www.imnr.com/
Copyright
Hybridon (AMEX:HBY)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Hybridon (AMEX:HBY)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024